More on UCBJY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $149.57 |
|
|||
| Open | $149.57 | ||||
| 52 Wk High | $46.25 | ||||
| 52 Wk Low | $32.74 | ||||
| Day High | $149.57 | ||||
| Day Low | $149.57 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,959 | ||||
- UCB (UCB:BB) (UCBJY) PT Raised to EUR305 at Deutsche Bank
- UCB Establishes the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines at Brigham and Women's Hospital
- UCB SA (UCB:BB) (UCBJY) PT Raised to EUR340 at TD Cowen
- FDA approves UCB's Zilbrysq autoinjector for myasthenia gravis
- UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis
- UCB Launches Wear It Out, a Community-Driven Program Created For and With People Living With Hidradenitis Suppurativa, Plaque Psoriasis, and Psoriatic Arthritis
- TD Cowen on UCB SA (UCB:BB) (UCBJY): 'Likely UCB Upside With Q4 HS Updates & Promising Pipeline'
- UCB Dedicates Site for New U.S. Biologics Manufacturing Campus in Georgia
- UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG
- BofA Securities Reiterates Buy Rating on UCB (UCB:BB) (UCBJY)
Entities mentioned with UCBJY
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Dividend | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Show More...
